Avenida de los Reyes, 1
Pol. Industrial La Mina – Norte Colmenar Viejo
34 91 846 60 00
Full-time employees: 515
|Mr. Jose Maria Fernandez Sousa-Faro||Founder, Exec. Chairman, CEO & Pres||294k||N/A||N/A|
|Mr. Pedro Francisco Fernandez Puentes||Exec. Vice-Chairman||124k||N/A||N/A|
|Mr. Juan Carlos-Torres Carretero||Founder||N/A||N/A||1949|
|Ms. María Luisa de Francia Caballero||Chief Financial Officer||N/A||N/A||N/A|
|Mr. José Luis Moreno Martinez-Losa||Director of Capital Markets & Investor Relations||N/A||N/A||N/A|
|Mr. Juan Gomez Pulido||Gen. Counsel & Sec. of the Board of Directors||N/A||N/A||N/A|
|Ms. Sandra Llamera Sanchez||Global Compliance Head||N/A||N/A||N/A|
|Ms. Lara Vadillo||Communication Director||N/A||N/A||N/A|
|Mr. Juan Nogues||Director of International Marketing & Sales||N/A||N/A||N/A|
|Ms. Belén Sopesén Veramendi Ph.D.||Director of Corp. Devel.||N/A||N/A||N/A|
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
Pharma Mar, S.A.’s ISS governance QualityScore as of 1 March 2023 is 7. The pillar scores are Audit: 8; Board: 9; Shareholder rights: 7; Compensation: 4.